FoxO1-GAB1轴调控慢性淋巴细胞白血病的归巢能力与基础AKT活性
研究比较CXCR4dimCD5bright与CXCR4brightCD5dim慢性淋巴细胞白血病(CLL)细胞的RNA表达谱,发现GAB1正向调控CXCR4brightCD5dim细胞的归巢能力,且FoxO1诱导的GAB1累积维持基础PI3K活性和静息CLL B细胞存活所需的「tonic」AKT磷酸化。GAB1抑制剂可诱导CLL细胞凋亡、损害迁移、抑制AKT磷酸化,并阻断伊布替尼治疗期间的代偿性AKT活性。
要点
- CXCR4/CD5克隆内亚群可用于研究CLL细胞迁移调控。
- FoxO1诱导的GAB1累积维持CLL细胞基础AKT磷酸化与存活。
- GAB1抑制剂单用或联合BTK抑制可诱导CLL细胞凋亡并阻断代偿AKT活性。
核心结论
- FoxO1-GAB1轴调控CLL细胞归巢能力及基础AKT活性,GAB1可作为治疗靶点。
- CLL细胞通过诱导FoxO1-GAB1-pAKT轴适应无法归巢至免疫微环境,该机制在伊布替尼治疗中重要。
研究设计与样本
- 对CXCR4dimCD5bright与CXCR4brightCD5dim CLL细胞进行RNA表达谱分析。
- 研究GAB1对CLL细胞归巢、基础PI3K/AKT活性及存活的影响,并测试新型GAB1抑制剂的治疗作用。
主要发现
- CXCR4brightCD5dim CLL细胞的归巢能力受GAB1正向调控。
- 免疫微环境外的CLL细胞中GAB1逐步累积由FoxO1诱导的转录激活介导。
- GAB1上调维持静息CLL B细胞存活所需的基础PI3K活性和「tonic」AKT磷酸化。
- 伊布替尼治疗时CLL细胞诱导FoxO1-GAB1-pAKT轴作为适应机制。
- GAB1抑制剂诱导CLL细胞凋亡、损害迁移、抑制tonic或BCR诱导的AKT磷酸化,并阻断伊布替尼治疗期间的代偿性AKT活性。
临床怎么用
- GAB1抑制剂可单用或联合BTK抑制用于靶向CLL细胞。
- 监测FoxO1-GAB1-pAKT轴可能有助于理解伊布替尼治疗中的适应机制。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Recirculation of chronic lymphocytic leukemia (CLL) cells between the peripheral blood and lymphoid niches plays a critical role in disease pathophysiology, and inhibiting this process is one of the major mechanisms of action for B-cell receptor (BCR) inhibitors such as ibrutinib and idelalisib. Migration is a complex process guided by chemokine receptors and integrins. However, it remains largely unknown how CLL cells integrate multiple migratory signals while balancing survival in the peripheral blood and the decision to return to immune niches. Our study provided evidence that CXCR4/CD5 intraclonal subpopulations can be used to study the regulation of migration of CLL cells. We performed RNA profiling of CXCR4dimCD5bright vs CXCR4brightCD5dim CLL cells and identified differential expression of dozens of molecules with a putative function in cell migration. GRB2-associated binding protein 1 (GAB1) positively regulated CLL cell homing capacity of CXCR4brightCD5dim cells. Gradual GAB1 accumulation in CLL cells outside immune niches was mediated by FoxO1-induced transcriptional GAB1 activation. Upregulation of GAB1 also played an important role in maintaining basal phosphatidylinositol 3-kinase (PI3K) activity and the "tonic" AKT phosphorylation required to sustain the survival of resting CLL B cells. This finding is important during ibrutinib therapy, because CLL cells induce the FoxO1-GAB1-pAKT axis, which represents an adaptation mechanism to the inability to home to immune niches. We have demonstrated that GAB1 can be targeted therapeutically by novel GAB1 inhibitors, alone or in combination with BTK inhibition. GAB1 inhibitors induce CLL cell apoptosis, impair cell migration, inhibit tonic or BCR-induced AKT phosphorylation, and block compensatory AKT activity during ibrutinib therapy.
引用
- Seda V, Vojackova E, Ondrisova L, et al. FoxO1-GAB1 axis regulates homing capacity and tonic AKT activity in chronic lymphocytic leukemia. Blood. 2021. PMID: 33786575. doi:10.1182/blood.2020008101
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。